热门资讯> 正文
VolitionRx Limited从比利时机构获得200万欧元的非稀释性资金
2026-03-31 20:45
- VolitionRx Limited (NYSE AMERICAN: VNRX) on Tuesday said that it secured €2.0 million in non-dilutive financing from Namur Invest and Wallonie Entreprendre.
- The company said it will use the proceeds to support development of its Nu.Q product portfolio, including regulatory transition work for Nu.Q NETs, as well as ongoing research and development of a lateral flow product aimed at improving access in low-income countries.
- Volition said the funding forms part of its strategy to secure non-dilutive financing to support continued development, adding that total non-dilutive funding to date exceeds $25 million.
- VNRX +0.05% premarket to $0.1901.
- Source: Press Release
More on VolitionRX
- VolitionRx receives NYSE non-compliance notice
- VolitionRx secures $2M financing through amended securities agreement; shares up
- Seeking Alpha’s Quant Rating on VolitionRX
- Historical earnings data for VolitionRX
- Financial information for VolitionRX
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
